Skip to main content
. Author manuscript; available in PMC: 2016 Apr 15.
Published in final edited form as: Cancer Res. 2015 Mar 13;75(8):1682–1690. doi: 10.1158/0008-5472.CAN-14-1855

Figure 3. VEGF-A KD retards tumorigenicity in WM1617 but not C8161 or A2058 melanoma xenografts.

Figure 3

A, Tumorigenicity assays revealed that VEGF-A KD (sh1) in WM1617 (A, left panel, n=5, 2 × 106 cells/mouse) resulted in significant growth inhibition in vivo. *, P<0.05. No growth alteration was observed in C8161 (A, middle panel, n=5, 2 × 106 cells/mouse) or A2058 (A, right panel, n=5, 2 × 106 cells/mouse) melanoma cell xenografts expressing VEGF-A shRNA (sh1) compared to nontarget control shRNA in vivo. B, VEGF-A KD in 100 µg of protein homogenates harvested from WM1617, C8161 and A2058 xenografts expressing nontarget control or VEGF-A shRNA (sh1) was confirmed using a human VEGF-A ELISA kit (n=5). *, P<0.05.